Bio-Rad Laboratories, Inc.
BIO
$238.68
-$2.34-0.97%
NYSE
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -2.46% | -3.92% | -5.16% | -7.46% | -6.26% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -2.46% | -3.92% | -5.16% | -7.46% | -6.26% |
| Cost of Revenue | -3.07% | -4.64% | -6.80% | -7.46% | -2.92% |
| Gross Profit | -1.92% | -3.29% | -3.73% | -7.46% | -8.99% |
| SG&A Expenses | -3.95% | -3.65% | -3.44% | -4.52% | -3.18% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -0.71% | -1.78% | -3.65% | -7.31% | -4.18% |
| Operating Income | -14.59% | -18.71% | -14.85% | -8.44% | -18.55% |
| Income Before Tax | -519.65% | -175.55% | -436.91% | -225.35% | -76.53% |
| Income Tax Expenses | -382.49% | -134.15% | -711.30% | -291.29% | -101.82% |
| Earnings from Continuing Operations | -571.33% | -189.38% | -388.82% | -209.46% | -68.58% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -571.33% | -189.38% | -388.82% | -209.46% | -68.58% |
| EBIT | -14.59% | -18.71% | -14.85% | -8.44% | -18.55% |
| EBITDA | -8.97% | -11.89% | -9.60% | -4.77% | -12.32% |
| EPS Basic | -637.13% | -202.81% | -376.52% | -216.46% | -63.76% |
| Normalized Basic EPS | -11.60% | -19.32% | -14.20% | -1.95% | -10.15% |
| EPS Diluted | -634.95% | -202.54% | -367.40% | -214.24% | -61.34% |
| Normalized Diluted EPS | -11.50% | -19.15% | -13.98% | -1.85% | -10.08% |
| Average Basic Shares Outstanding | -3.01% | -3.41% | -3.47% | -3.01% | -2.56% |
| Average Diluted Shares Outstanding | -3.10% | -3.61% | -3.71% | -3.08% | -2.63% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |